Bristol Myers Squibb at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Bristol Myers Squibb takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8069. Its program centres on non-small cell lung cancer, looking at how current treatment choices play out today and where they are heading. It also covers new treatment strategies in prostate and bladder cancer.

OrganizationESMO 2026 Attendance
bms.com
Large pharmaExhibitor
Global pharmaceutical company whose oncology medicines include nivolumab, ipilimumab and nivolumab plus relatlimab.
Booth
Exhibiting at Booth 8069
Satellite
Fri Oct 23
09:45–11:15
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
Sponsored session · with Hospital Universitario Puerta de Hierro Majadahonda, European Institute of Oncology (IEO), Vall d'Hebron University Hospital
Lung & thoracic cancers
Satellite
Sat Oct 24
13:00–14:30

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Bristol Myers Squibb

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction